Back to Journals » OncoTargets and Therapy » Volume 12

Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma

Authors Wang Y, Yu W, He M, Huang Y, Wang M, Zhu J

Received 1 October 2018

Accepted for publication 8 December 2018

Published 31 December 2018 Volume 2019:12 Pages 359—364

DOI https://doi.org/10.2147/OTT.S189425

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche


Yu Wang,1,* Weixin Yu,1,* Mingqing He,2,* Yan Huang,3 Mingyue Wang,4 Jinzhou Zhu5

1Department of General Surgery, Jintan Affiliated Hospital of Jiangsu University, Changzhou, China; 2Department of Geriatrics, The First Affiliated Hospital of Soochow University, Suzhou, China; 3Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; 4Department of Ultrasonography, The First Affiliated Hospital of Soochow University, Suzhou, China; 5Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China

*These authors contributed equally to this work

Background: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC.
Methods: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy.
Results: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all P<0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, P=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, P<0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (P=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]).
Conclusion:
Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy.

Keywords: alpha-fetoprotein, biomarker, cytoskeleton-associated protein 4, hepatocellular carcinoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]